In first for European Union, anti-skin cancer drug approved             AFP  27th Apr 2019 10:10:38 GMT +0300 AFP  27th Apr 2019 10:10:38 GMT +0300 AFP   French pharmaceutical giant Sanofi's new tumour-reducing drug is aimed at patients with the second most common form of skin cancer whose cancer is advanced and are who are not candidates for surgery or radiation therapy. [AFP]  French pharmaceutical giant Sanofi's new tumour-reducing drug is aimed at patients with the second most common form of skin cancer whose cancer is advanced and are who are not candidates for surgery or radiation therapy. [AFP] French pharmaceutical giant Sanofi's new tumour-reducing drug is aimed at patients with the second most common form of skin cancer whose cancer is advanced and are who are not candidates for surgery or radiation therapy  googletag.cmd.push(function() { googletag.display('div-gpt-ad-1498022554617-0'); });       Register to advertise your products & services on our classifieds website Digger.co.ke and enjoy one month subscription free of charge and 3 free ads on the Standard newspaper. Register to advertise your products & services on our classifieds website Digger.co.ke and enjoy one month subscription free of charge and 3 free ads on the Standard newspaper. Digger.co.ke Related Topics Anti-skin cancer drug Skin cancer Cancer